arGEN-X Advances ARGX-113 Into Preclinical Development for Autoimmune Disorders
4/24/2013 10:02:14 AM
More...
|
arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3/25/2013 9:47:36 AM
More...
|
arGEN-X Launches NHance(TM) Technology to Generate Better Human Antibody Therapies
3/19/2012 9:05:59 AM
More...
|
arGEN-X Appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel
3/19/2012 9:04:54 AM
More...
|
arGEN-X Enters Into a Therapeutic Antibody Alliance With Shire plc
2/29/2012 8:17:31 AM
More...
|
arGEN-X Advances a Third Therapeutic Antibody Program into Preclinical Development
2/8/2012 9:43:15 AM
More...
|
arGEN-X is Awarded €1.3 Million IWT Grant to Advance Proprietary SIMPLE Antibody(TM) Platform for Addressing Challenging Disease Targets
12/19/2011 9:56:21 AM
More...
|
arGEN-X Raises $37 Million in Oversubscribed Series B Round
12/1/2011 6:51:34 AM
More...
|
arGEN-X Presents Significant Progress at BioPharm America 2011
9/7/2011 11:24:54 AM
More...
|
arGEN-X Announces Non-exclusive License with BioWa for Potelligent® Technology
7/26/2011 11:43:41 AM
More...
|
|